On June 24, 2024, Fosun Pharma (600196.SH; 02196.HK) announced that it intends to privatize its subsidiary, Henlius (02696.HK), through a merger by absorption.

The cash consideration for this absorption and merger transaction is HK$24.6 per share, which is a premium of 36.67% to the closing price of Henlius H shares on the undisturbed date; and a premium of 52.04% to the 30 trading days prior to the undisturbed date. The aggregate cash consideration for the Merger by Absorption shall not exceed approximately HK$5,407 million or its equivalent in RMB.

As a core innovative asset of Fosun Pharma, Fuhong Henlius, upon completion of the transaction, will contribute to the sustainable growth of Fuhong Henlius as well as strengthen Fosun Pharma's strategic layout in the field of innovative biopharmaceuticals.

Henlius, as an international innovative biopharmaceutical company, is committed to providing affordable and high-quality biopharmaceuticals to patients around the world, with products covering oncology, autoimmune diseases, ophthalmology, etc. Henlius has already marketed 5 products in China and 3 products internationally, with 23 approved indications, including Hanlikon® (Rituximab), the first domestically produced biosimilar to be marketed, and the first domestically produced monoclonal antibody to be approved in both China and the US, as well as the first domestically produced monoclonal antibody approved in both China and the EU, US, the first domestic monoclonal antibody biosimilar approved in China, Europe and the US, Henlius® (trastuzumab, trade name: HERCESSI™ in the US and Zercepac® in Europe), and the world's first anti-PD-1 monoclonal antibody approved for the first-line treatment of small-cell lung cancer, HanShizi® (srulizumab). 2023, Henlius had operating revenues of 5,395 million yuan and net profit of 546 million yuan, and first time to realized a full-year profit.

https://mp.weixin.qq.com/s?__biz=MjM5NTM3OTYwNA==&mid=2650496590&idx=1&sn=7fa6c4f6d61419fea82ee891af4a06f3&chksm=bef69eb5898117a3716d50c7d3a90a07fdcad676b722e59a35ae032f787556beaf4157906540&mpshare=1&scene=1&srcid=0626z7FzoNlqsSevoUSPYax9&sharer_shareinfo=649c1ba3fbb314b1f83418da1cea1663&sharer_shareinfo_first=649c1ba3fbb314b1f83418da1cea1663#rd